Prestige Consumer Healthcare (PBH) is back in focus after fiscal 2026 earnings missed estimates, revenue declined year over year, and guidance for fiscal 2027 came in below consensus expectations.

Those weaker fiscal 2026 results, cautious fiscal 2027 guidance, and the new investor investigation have coincided with a sharp loss of momentum, with Prestige Consumer Healthcare’s share price down 25.1% over 90 days and its 1 year total shareholder return falling 44.2%.

If this shift in sentiment has you reassessing opportunities in healthcare, it may be worth scanning for other self care and treatment companies using a focused screener such as 39 healthcare AI stocks.

With Prestige Consumer Healthcare stock now down sharply and trading at a sizeable discount to some analyst targets, the key question is whether recent setbacks are already reflected in the price or if markets are anticipating weaker growth ahead.

Most Popular Narrative: 30.1% Undervalued

Prestige Consumer Healthcare is currently trading at $46.67, while the most followed narrative anchors fair value at $66.80. This creates a sizable valuation gap that rests on detailed earnings, margin, and discount rate assumptions.

Prestige's strong and consistent free cash flow generation (~$245 million projected for the year) provides financial flexibility for continued deleveraging and opportunistic share repurchases, supporting future earnings per share (EPS) growth and value for shareholders.

Want to see what sits behind that cash flow confidence? The narrative leans heavily on revenue compounding, firmer margins, and a future earnings multiple that all need to line up.

Result: Fair Value of $66.80 (UNDERVALUED)

However, Prestige Consumer Healthcare still faces meaningful risks, including ongoing Clear Eyes supply constraints and heavy reliance on a handful of mature OTC brands that could limit future growth.

Next Steps

With mixed sentiment around Prestige Consumer Healthcare and its outlook, now is a good time to review the underlying data yourself and decide where you stand based on the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Prestige Consumer Healthcare?

If you stop at Prestige Consumer Healthcare, you risk missing other opportunities that could fit your goals, so widen your search using targeted stock ideas on Simply Wall Street’s screener.

• Target resilient, income focused opportunities by reviewing companies identified as potential yield standouts in the 9 dividend fortresses.
• Hunt for quality at a reasonable price by scanning stocks highlighted in the 47 high quality undervalued stocks.
• Prioritize stability and financial strength by focusing on companies surfaced in the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.